Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics, Inc. Common Stock (NMRA) Revenue
Annual & quarterly revenue history · segment & region breakdown
NMRA · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsNeumora Therapeutics, Inc. Common Stock trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2020 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare NMRA revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Neumora Therapeutics, Inc. Common Stock receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Neumora Therapeutics, Inc. Common Stock reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Neumora Therapeutics, Inc. Common Stock's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NMRA revenue · 4 questionsNMRA's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Neumora Therapeutics, Inc. Common Stock SEC filings · GAAP · Neumora Therapeutics, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026